Jazz Q2 GAAP net loss $718M; revenue $1.05B up 2%; updates FY25 guidance

Jazz Pharmaceuticals plc

2025-Q2 EPS reported -$13.28 revenue$1,943,553,000

Q2 total revenues $1.05B, up 2% YoY; GAAP net loss $718.5M vs $168.6M profit in Q2 2024.
Non-GAAP adjusted net loss $504.8M vs $360.7M income; FY2025 revenue guidance revised to $4.15-$4.30B.
Xywav revenue +13% to $415.3M; added ~625 net patients in Q2, active patients ~15,225.
Renee Gala named President and CEO effective Aug 11; Bruce Cozadd becomes Chairman.
FDA Priority Review for Zepzelca combo in 1L ES-SCLC (PDUFA Oct 7); dordaviprone PDUFA Aug 18.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.